Ascentage Pharma Receives FDA Clearance for Novel BTK Protein Degrader APG-3288 in B-Cell Malignancies
Key Insights
Ascentage Pharma (search)'s novel BTK (search) protein degrader APG-3288 (search) has received FDA IND clearance for a global Phase I study in patients with relapsed/refractory B-cell malignancies (search).
APG-3288 (search) utilizes PROTAC technology to achieve complete degradation of both wild-type BTK (search) and resistant mutants, potentially overcoming resistance to existing BTK inhibitors.
The drug demonstrated superior BTK (search) degradation, higher selectivity, and more favorable pharmacokinetic properties compared to other BTK degraders in preclinical studies.
Ascentage Pharma (search) Group International has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (search)'s clearance of its investigational new drug application for APG-3288 (search), a novel next-generation Bruton tyrosine kinase (search) (BTK (search))-targeted protein degrader. The FDA clearance enables the company to initiate a global Phase I clinical study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies (search), marking Ascentage Pharma's entry into the field of targeted protein degradation.
Revolutionary PROTAC Technology Platform
APG-3288 (search) represents the first novel, highly potent and selective BTK (search) degrader developed using Ascentage Pharma (search)'s proprietary proteolysis-targeting chimera (PROTAC) technology platform. Unlike conventional BTK inhibitors that merely block the protein's function, APG-3288 induces the formation of a ternary complex consisting of the BTK target, the PROTAC molecule, and the Cereblon E3 ubiquitin ligase (search), leading to proteasome-mediated degradation of the BTK target.
This degradation approach offers several advantages over traditional inhibition strategies. APG-3288 (search) is designed to induce rapid, potent, highly selective, and sustained degradation of both wild-type BTK (search) and multiple BTK mutants associated with resistance to existing BTK inhibitors. By blocking the BCR-BTK signaling axis at its source, this approach potentially overcomes resistance mechanisms that limit the effectiveness of current BTK inhibitors.
Addressing Critical Unmet Medical Need
BTK (search) serves as a key kinase in the B-cell receptor signaling pathway and plays a central role in the activation, proliferation, and survival of B-cells. Aberrant BTK activation is closely associated with the initiation and progression of multiple B-cell malignancies (search), including B-cell lymphoma (diffuse large B-cell lymphoma (search), mantle cell lymphoma (search), and follicular lymphoma (search)), chronic lymphocytic leukemia (search), and Waldenström's macroglobulinemia (search).
While BTK (search) inhibitors have drastically improved treatment outcomes for patients with B-cell malignancies (search), BTK mutations and remodeling of signaling pathways often lead to acquired resistance during prolonged treatment. This creates an urgent clinical need for new drugs with novel mechanisms of action that can overcome these resistance patterns.
Superior Preclinical Performance
In preclinical studies, APG-3288 (search) demonstrated superior performance compared to other BTK (search) degraders in development. The compound showed more potent BTK degradation, higher selectivity, and more favorable pharmacokinetic properties, highlighting its therapeutic potential.
"Compared to existing conventional BTK (search) inhibitors, Ascentage Pharma (search)'s BTK degraders developed with our PROTAC technology can achieve complete degradation of target protein and are enabled by a molecular mechanism that can induce stronger efficacy," said Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma. "APG-3288 (search) represents a strategic clinical stage candidate in the field of BTK-targeted therapies. Its high selectivity, potency, and consistent PK/PD profiles across multiple BTK-resistant models fully validate our differentiated design capabilities of PROTAC-based therapeutic candidates."
Global Phase I Study Design
The upcoming clinical trial will be a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of APG-3288 (search) in patients with relapsed/refractory hematologic malignancies. This study represents a critical step in advancing APG-3288 toward potential regulatory approval and commercial availability.
Strategic Pipeline Expansion
The FDA clearance represents a major milestone for Ascentage Pharma (search)'s strategic pipeline expansion and underscores the company's persistent innovation in hematologic malignancies. Dr. Zhai noted that this clearance "lays a strong foundation for our future exploration of the combinatory potential between APG-3288 (search) and our existing proprietary small-molecule agents."
The company plans to accelerate the global clinical development of APG-3288 (search) and actively explore the therapeutic potential of protein degraders in hematologic malignancies and other BTK (search)-driven diseases. Beyond oncology applications, BTK also plays a critical role in BCR- and Fc receptor-mediated signal transduction in innate immune cells, and aberrant BTK activation has been implicated in various autoimmune and inflammatory diseases, suggesting potential broader therapeutic applications.
This regulatory achievement officially opens a new chapter in Ascentage Pharma (search)'s clinical development in targeted degradation and represents another major expansion to the company's global innovative pipeline, which already includes approved products Olverembatinib and Lisaftoclax for various hematologic malignancies.